Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyUrologic OncologyDiseaseNeuroendocrine CarcinomaProstate CancerSubgroupICD10C61C80.9MeSHCarcinoma, NeuroendocrineProstatic NeoplasmsSequenceChemotherapyChemo-substanceCisplatinEtoposideChemo-substanceCisplatinEtoposideChemo-substanceCisplatinEtoposideChemo-substanceCisplatinEtoposideNo. Substances2 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances7Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorApostolidis LDiseaseNeuroendokrines Prostatakarzinom, Erst- und ZweitlinieOriginDepartment of Medical Oncology, University Hospital HeidelbergProtocols in Revision 1 protocol foundProtocols under revision.Cisplatin 25 / Etoposide 100, Neuroendocrine Prostate Cancer (PID1283 V1.1)
